<DOC>
	<DOCNO>NCT00003728</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . It yet know regimen combination chemotherapy plus steroid therapy effective acute lymphoblastic leukemia lymphoblastic non-Hodgkin 's lymphoma . PURPOSE : Randomized phase III trial compare effectiveness different regimen combination chemotherapy plus steroid therapy treat child acute lymphoblastic leukemia lymphoblastic non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Combination Chemotherapy Plus Steroid Therapy Treating Children With Acute Lymphoblastic Leukemia Lymphoblastic Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - Compare value dexamethasone ( DM ) v prednisolone ( PRDL ) administer induction therapy , term event-free overall survival , child acute lymphoblastic leukemia ( ALL ) lymphoblastic non-Hodgkin 's lymphoma ( LNHL ) . - Assess value increase number administration asparaginase consolidation late intensification therapy , term disease-free overall survival , child without high-risk ( VHR ) feature . - Compare response rate child treat prephase therapy comprise DM v PRDL intrathecal methotrexate . - Compare incidence grade toxic effect treatment regimens child . - Compare long-term effect treatment regimens growth pubertal development , neurocognitive , cardiac , endocrine function , incidence aseptic bone necrosis child . - Evaluate proportion child VHR disease define accord extend VHR criterion , assess prognostic importance new VHR feature ( cytogenetics minimal-residual disease ) . - Compare feasibility VHR chemotherapy protocol patient treat DM v PRDL . OUTLINE : This randomize , multicenter study . Patients stratified prephase therapy accord center , disease ( acute lymphoblastic leukemia [ ALL ] vs non-Hodgkin 's lymphoma [ NHL ] ) , WBC ALL patient ( less 10,000/mm^3 v 10,000/mm^3 less 100,000/mm^3 v great 100,000/mm^3 ) , stage NHL patient ( I II v III IV ) , whether prephase already start ( yes v ) . Patients stratify protocol II therapy accord center , risk group ( low risk [ VLR ] v average risk 1 [ AR1 ] v average risk 2 [ AR2 ] ) , treatment arm first randomization . - Prephase : Patients randomize 1 2 treatment arm - Arm I : Patients receive oral prednisolone ( PRDL ) twice daily methylprednisolone IV 1 hour every 12 hour day 1-7 . - Arm II : Patients receive dexamethasone ( DM ) orally twice daily IV 1 hour every 12 hour day 1-7 . Patients arm also receive methotrexate ( MTX ) intrathecally ( IT ) day 1 . - Protocol IA ( day 8-35 ) : - VLR patient : Patients receive either oral PRDL oral DM ( depend early randomization ) day 8-28 ; vincristine ( VCR ) IV day 8 , 15 , 22 , 29 ; daunorubicin ( DNR ) IV 1-4 hour day 8 15 ; MTX IT day 12 25 ; asparaginase ( ASP ) IV 1 hour intramuscularly ( IM ) day 12 , 15 , 18 , 22 , 25 , 29 , 32 , 35 . - AR1 patient : Patients receive PRDL DM , VCR , ASP manner VLR patient . Patients also receive DNR IV 1-4 hour day 8 , 15 , 22 , 29 triple intrathecal therapy ( TIT ) comprise MTX , cytarabine ( ARA-C ) , hydrocortisone day 12 25 . - AR2 high-risk ( VHR ) patient : Patients receive PRDL DM , VCR , ASP manner VLR patient high-dose MTX ( HD-MTX ) IV 24 hour day 8 ; cyclophosphamide ( CTX ) IV 1 hour day 9 ; DNR IV 1-4 hour day 15 , 22 , 29 ; TIT day 12 25 . Patients VLR , AR1 , AR2 disease protocol IA proceed protocol IB , interval therapy , protocol II . Patients VHR disease protocol IA proceed VHR patient protocol . - Protocol IB ( VLR , AR1 , AR2 patient ) : Patients precursor B-cell ALL must complete remission ( CR ) patient NHL must CR good partial remission . - VLR patient : Patients receive oral mercaptopurine ( MP ) day 36-63 ; ARA-C IV day 38-41 , 45-48 , 52-55 , 59-62 ; MTX IT day 38 52 . - AR1 AR2 patient : Patients receive oral MP ARA-C manner VLR patient ; CTX IV 1 hour day 36 63 ; TIT day 38 52 . - VLR , AR1 , AR2 patient also randomize 1 2 treatment arm . - Arm I : Patients receive ASP IV IM day 38 , 41 , 45 , 48 , 52 , 55 , 59 , 62 . - Arm II : Patients receive ASP . - Interval therapy VLR , AR1 , AR2 patient ( begin 14 day completion protocol I ) : Patients receive oral MP daily day 1-56 ; HD-MTX IV 24 hour day 8 , 22 , 36 , 50 ; leucovorin calcium ( CF ) ( levofolinic acid ) orally IV begin 36 hour initiation MTX infusion repeat every 6 hour hour 72 serum MTX level adequate ; TIT day 9 , 23 , 37 , 51 . - Protocol II ( reinduction therapy IIA reconsolidation therapy IIB ) : - VLR patient : Patients receive oral DM twice daily day 1-21 ; VCR IV day 8 , 15 , 22 , 29 ; doxorubicin ( DOX ) IV 1-4 hour day 8 15 ; ARA-C IV day 38-41 45-48 ; oral thioguanine ( TG ) daily day 36-49 ; MTX IT day 38 . - AR patient : Patients receive DM , VCR , ARA-C , TG manner VLR patient ; DOX IV 1-4 hour day 8 , 15 , 22 , 29 ; CTX IV 30-60 minute day 36 ; TIT day 38 . - VLR AR patient also randomize 1 2 treatment arm . - Arm I : Patients receive short-term ASP IV 1 hour IM day 8 , 11 , 15 , 18 . - Arm II : Patients receive long-term ASP IV 1 hour IM day 8 , 11 , 15 , 18 , 22 , 25 , 29 , 32 . - Maintenance therapy VLR AR patient ( begin 14 day completion protocol II ) : - VLR patient : Patients receive oral MP daily oral MTX weekly total 74 week . - AR1 patient : Patients receive oral MP daily day 1-70 ; oral MTX day 1 , 8 , 15 , 29 , 36 , 43 , 50 , 57 , 64 ; TIT day 22 . Treatment repeat every 10 week 6 course . - AR2 patient : Patients receive MP oral MTX ( AR1 patient ) ; HD-MTX IV 24 hour day 22 ; CF interval therapy day 23 24 ; TIT ASP day 23 . After course 6 , AR1 AR2 patient receive maintenance therapy comprise oral MP daily oral MTX week . - VHR patient protocol ( recommended treatment ) : Patients VHR disease protocol IA receive reinforce consolidation ( protocol IB ' ) VANDA regimens . - Protocol IB ' : Patients receive oral DM twice daily day 36-40 50-54 ; oral MP daily day 36-40 ; VCR IV day 36 41 ; HD-MTX IV 24 hour day 36 50 ; TIT day 37 51 ; ARA-C IV 3 hour every 12 hour day 40 ; ASP IV 1 hour IM day 41 , 43 , 45 , 55 , 57 , 59 ; oral TG daily day 50-54 ; vindesine ( DAVA ) IV day 50 ; DNR IV 1-4 hour day 54 ; CTX IV 1 hour day 52 53 . Patients achieve CR protocol IB ' proceed VANDA regimen . - VANDA regimen : Patients receive oral DM twice daily day 1-5 ; ARA-C IV 3 hour every 12 hour day 1 2 ; mitoxantrone IV 1 hour day 3 4 ; etoposide ( VP-16 ) IV 1 hour day 3-5 ; TIT day 5 ; ASP IV IM day 7 , 9 , 11 , 13 . After protocol IB ' VANDA , VHR patient eligible stem cell transplantation ( SCT ) HLA-compatible familial donor undergo transplantation . Patients ineligible SCT receive interval therapy , follow 2 sequence block R1 , R2 , R3 ( 2 course block total 6 course ) , maintenance therapy total treatment duration 2 year . - Interval therapy : Patients receive oral MP daily day 1-42 ; HD-MTX IV 24 hour day 8 , 22 , 36 ; CF interval therapy ( describe ) ; TIT day 9 , 23 , 37 . - Blocks R1 , R2 , R3 ( sequential regimen repeat ) : - R1 : Patients receive oral DM twice daily oral MP daily day 1-5 ; VCR IV day 1 6 ; HD-MTX IV 24 hour day 1 ; CF interval therapy day 1 2 ; TIT day 2 ; ARA-C IV 3 hour every 12 hour day 5 ; ASP IV 1 hour IM day 6 . - R2 : Patients receive DM , HD-MTX , CF , TIT , ASP block R1 oral TG daily day 1-5 ; DAVA IV day 1 ; CTX IV 1 hour day 3 4 ; DNR IV 1-4 hour day 5 . - R3 : Patients receive DM ASP block R1 ARA-C IV 3 hour every 12 hour day 1 2 ; VP-16 IV 1 hour day 3-5 ; TIT day 5 . - Maintenance therapy : ( begin 14 day second course block R3 end 2 year initiation study therapy ) : Patients receive treatment maintenance therapy AR1 patient . Treatment repeat every 10 week 5 course . Patients follow every 3 month 5 year annually thereafter . PROJECTED ACCRUAL : A total 1,400-1,500 patient accrue study within 5.5 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
	<mesh_term>Cortisol succinate</mesh_term>
	<mesh_term>Hydrocortisone acetate</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Hydrocortisone</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<mesh_term>6-Mercaptopurine</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Vindesine</mesh_term>
	<mesh_term>Thioguanine</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm acute lymphoblastic leukemia ( ALL ) FAB L1 L2 morphology Positive SIg allow OR Histologically confirm precursor B precursor T lymphoblastic nonHodgkin 's lymphoma ( NHL ) No diffuse large cell Bcell lymphoma , Burkitt 's lymphoma , highgrade Bcell lymphoma ( Burkittlike ) Very lowrisk ( VLR ) patient meet 1 follow criterion : ALL Bcell lineage WBC le 10,000/mm^3 Must meet 1 follow condition : DNA index great 1.16 less 1.50 chromosome number 5166 unknown DNA index assess chromosome number 5166 DNA index great 1.16 less 1.50 chromosome number unknown Good response prephase therapy Absence ( 9 ; 22 ) BCR/ABL , ( 4 ; 11 ) /MLLAF4 , 11q23/MLL rearrangement No acute undifferentiated leukemia ( AUL ) No CNS gonadal involvement Precursor Blymphoblastic NHL stage I II OR Average risk ( AR ) patient : Must meet 1 follow criterion : ALL good response prephase therapy neither VLR high risk ( VHR ) VLR ALL CNS involvement ( CSF positive negative ) Precursor Blymphoblastic NHL stage III IV without VHR feature Precursor Tlymphoblastic NHL AR patient substratified : AR1 : Bcell lineage ALL WBC less 100,000/mm^3 Surreptitious hemorrhagic CSF become negative D4 prephase therapy Precursor Blymphoblastic NHL stage III IV Precursor Tlymphoblastic NHL stage I II AR2 : Bcell lineage ALL WBC least 100,000/mm^3 Tcell lineage ALL regardless WBC Overt nonequivocal CNS involvement D0 CSF involvement D4 Gonadal involvement Precursor Tlymphoblastic NHL stage III IV Newborn Down syndrome patient AR2 feature assign AR1 group OR VHR patient : Must meet 1 follow criterion : ALL patient meet 1 follow condition : Poor response prephase therapy ( least 1,000/mm^3 blast peripheral blood completion prephase therapy ) ( 9 ; 22 ) BCR/ABL ( 4 ; 11 ) /MLLAF4 = 11q23/MLL rearrangement Near haploidy ( 34 chromosome DNA index le 0.7 ) Hypodiploid ( 3540 chromosome DNA index 0.7 0.8 ) AUL For B lineage ALL : failure achieve complete response ( CR ) completion protocol IA For T lineage ALL : failure achieve CR good partial response ( GPR ) completion protocol IA Minimalresidual disease ( great 1,000 blasts/100,000 mononuclear bone marrow cell ) evaluation IA ( day 35 ) NHL patient fail achieve CR GPR completion protocol IA All VHR patient eligible stem cell transplantation except whose sole VHR criterion poor response prephase therapy none follow feature : Tcell immunophenotype Early B ALL ( CD10 negative ) WBC least 100,000/mm^3 Newborn Down syndrome patient VHR feature assign AR1 group NOTE : A new classification scheme adult nonHodgkin 's lymphoma adopt PDQ . The terminology `` indolent '' `` aggressive '' lymphoma replace former terminology `` low '' , `` intermediate '' , `` high '' grade lymphoma . However , protocol us former terminology . PATIENT CHARACTERISTICS : Age : Under 18 Performance status : Not specify Life expectancy : Not specify Hematopoietic : See Disease Characteristics Hepatic : Not specify Renal : Not specify PRIOR CONCURRENT THERAPY : Biologic therapy : See Disease Characteristics Chemotherapy : Not specify Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : Not specify Other : No prior therapy</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>stage I childhood lymphoblastic lymphoma</keyword>
	<keyword>stage II childhood lymphoblastic lymphoma</keyword>
	<keyword>stage III childhood lymphoblastic lymphoma</keyword>
	<keyword>stage IV childhood lymphoblastic lymphoma</keyword>
	<keyword>untreated childhood acute lymphoblastic leukemia</keyword>
	<keyword>L1 childhood acute lymphoblastic leukemia</keyword>
	<keyword>L2 childhood acute lymphoblastic leukemia</keyword>
	<keyword>T-cell childhood acute lymphoblastic leukemia</keyword>
	<keyword>B-cell childhood acute lymphoblastic leukemia</keyword>
	<keyword>acute undifferentiated leukemia</keyword>
</DOC>